Prostratin: Activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART

Blood

Volumn 98, Issue 10, 2001, Pages 3006-3015

  Kulkosky, Joseph ^a,b   Culnan, Derek M ^a,b   Roman, Jeanette ^a,b   Dornadula, Geethanjali ^a,b   Schnell, Matthias ^a,b   Boyd, Michael R ^a,b   Pomerantz, Roger J ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 DEOXYPHORBOL 13 ACETATE; CHEMOKINE RECEPTOR CXCR4; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; PHORBOL ESTER DERIVATIVE; PROSTRATIN; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0035892120     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.10.3006     Document Type: Article

References (36)

1. Gustafson KR, Cardellina JH, McMahon JB, et al. A non-promoting phorbol from the Samoan medicinal plant, Homalanthus nutans, inhibits cell killing by HIV-1. J Med Chem. 1992;35:1978-1986.
2. Gulakowski RJ, McMahon JB, Buckhiet RW Jr, Gustafson KR, Boyd MR. Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immuno-deficiency virus (HIV). Antiviral Res. 1997;33:2 87-97.
3. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active anti-retroviral therapy. Science. 1997;278:1295-1300.
4. Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in the blood plasma of patients on suppressive highly active anti-retroviral therapy (HAART). JAMA. 1999;282:1627-1632.
5. Zhang H, Dornadula G, Beumont M, et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med. 1998;339;1803-1809.
6. Gallagher R, Collins S, Trujillo J, et al. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood. 1979;54:713-733.
7. Tsuchiya S, Yamabe M, Yamaguchi Y, et al. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer. 1980;26:171-176.
8. Collins SJ. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation and cellular oncogene expression. Blood. 1987;70:1233-1244.
9. Janeway CA Jr, Travers P, Hunt S, Walport M. Immunobiology: The Immune System in Health and Disease. 3rd ed. New York, NY: Current Biology; 1997.
10. Maliik N, Greenfield BW, Wahl AF, Kiener PA. Activation of human monocytes through CD40 induces matrix metalloproteinases. J Immunol. 1996;156:3952-3960.
11. + T cells. Science. 1995;15:1811-1815.
12. Cox PA. Will tribal knowledge survive the millennium? Science. 2000;287:44-45.
13. Fursenberger G, Berry DL, Sorg B, Marks F. Skin tumor promotion by phorbol esters is a two-stage process. Proc Natl Acad Sci U S A. 1981;78:7722-7726.
14. Kulkosky J, Laptev A, Shetty S, et al. Human immunodeficiency virus type 1 Vpr alters bone marrow cell function. Blood. 1999;93:1906-1915.
15. Szallasi Z, Blumberg PM. Prostratin, a non-promoting phorbol ester, inhibits induction by phorbol-12-myristate-13-acetate of ornithine decarboxylase, edema and hyperplasia in CD-1 mouse skin. Cancer Res. 1991;51:5355-5360.
16. Szallasi Z, Kratisa KW, Blumberg PM. Non-promoting-12-deoxyphorbol-13-esters as potent inhibitors of phorbol-12-myristate-13-acetate-induced acute and chronic biological responses in CD-1 mouse skin. Carcinogenesis. 1992;13:2161-2167.
17. Szallasa A, Kramanovic L, Blumberg PM. Non-promoting 12-deoxyphorbol-13-esters inhibit phorbol myristate-13-acetate induced tumor promotion in CD-1 mouse skin. Cancer Res. 1993;52:2507-2512.
18. Jeon YJ, Han SH, Lee YW, Lee M, Yang KH, Kim HM. Dexamethasone inhibits IL-1 beta gene expression in LPS-stimulated RAW 264.7 cells by blocking NF kappa B/Rel and AP-1 activation. Immunopharmacology. 2000;20:173-183.
19. Malyankar UM, Scantena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. Osteoprotegerin is an alphavbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem. 2000;275:20959-20962.
20. Xu L, Fidler IJ. Acidic pH-induced elecation in interleukin 8 expression by human ovarian carcinoma cells. Cancer Res. 2000;15:4610-4616.
21. Yokoo T, Kitamura M. Dual regulation of IL-1 beta-mediated matrix metalloproteinases-9 expression in mesangial cells by NF-kappa B and AP-1. Am J Physiol. 1996;270:F123-130.
22. Folgueira L, McElhinny JA, Bren GD, et al. Protein kinase c-zeta mediates NF kappa B activation in human immunodeficiency virus-infected monocytes. J Virol. 1995;70:223-231.
23. Salmon P, Giovane A, Wasylyk B, Klatzmann D. Characterization of the human CD4 gene promoter: transcription from the CD4 gene core promotor is tissue-specific and is activated by Ets proteins. Proc Natl Acad Sci U S A. 1993;90:7739-7743.
24. Castillo AI, Tolon RM, Aranda A. Insulin-like growth factor-1 stimulates rat prolactin gene expression by Ras, Ets and phosphatidylinositol 3-kinase dependent mechanism. Oncogene. 1998;16:1981-1991.
25. Karmura T, Handa H, Hamasaki N, Kitajima S. Characterization of the human thrombopoietin gene promoter: a possible role of an Ets transcription factor, E4TF1/GABP. J Biol Chem. 1997;272:17:11361-11368.
26. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278:1291-1295.
27. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active anti-retroviral therapy. Proc Natl Acad Sci U S A. 1997;94:13193-13197.
28. + T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A. 1998;95:8869-8873.
29. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999;340:1605-1613.
30. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med. 1999;340:1614-1622.
31. + T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med. 1999;5:651-655.
32. Prins JM, Jurrianns S, van Praag RME, et al. Immuno-activation with anti-CD3 and recombinant human IL-2 and HIV-1-infected patients on potent antiretroviral therapy. AIDS. 1999;13:2405-2410.
33. Sonza S, Mutimer HP, Oelrichs R, et al. Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active retroviral therapy. AIDS. 2000;15:17-22.
34. Pomerantz RJ. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. Biomed Pharmacother. 2000;55:1-9.
35. Bergamini A, Perno CF, Dini L, et al. Macrophage colony-stimulating factor enhances the susceptibility of macrophages to infection by human immunodeficiency virus and reduces the activity of compounds that inhibit virus binding. Blood. 1994;84:3405-3412.
36. Dornadula G, Nunnari G, Vanella M, et al. HIV-1 infected individuals with residual disease on suppressive HAART can be stratified into relevant virological and immunological subgroups. J Infect Dis. 2001;183:1682-1687.